
TwinStrand Biosciences: Pioneering DNA sequencing tech for faster, life-saving decisions.
TwinStrand Biosciences, founded in Seattle, focuses on revolutionizing DNA sequencing with its proprietary Duplex Sequencing technology. The company's core mission is to enable faster and more accurate life-saving decisions for physicians, patients, and drug researchers. TwinStrand offers a range of products and services, including AML assays, mutagenesis assays, nitrosamine testing, and custom sequencing solutions. Their market focus spans healthcare providers, pharmaceutical companies, and research institutions.
Notable figures affiliated with TwinStrand Biosciences include key investors and advisors from leading biotech and genomics fields. The company has achieved significant milestones, such as the publication of groundbreaking research on measuring minimal residual disease (MRD) in acute myeloid leukemia (AML). TwinStrand's impact is evident in its contributions to enhancing the precision of genetic testing and advancing personalized medicine.

Twist Bioscience

SeqLL
seqll.com

XGenomes
xgenomes.com

10x Genomics
10xgenomics.com

SeqOnce Biosciences
seqonce.com

Molecular Loop

Sequencing.com
sequencing.com

Dnanexus
dnanexus.com

Parse Biosciences

Data Driven Bioscience

Sequegenics
sequegenics.com

Lightspeed Genomics

seqWell
seqwell.com

Toma Biosciences
tomabio.com

Electronic Biosciences
electronicbio.com
Companies similar to TwinStrand Biosciences include Twist Bioscience, SeqLL, XGenomes and 10x Genomics.
TwinStrand Biosciences was founded in 2015.
TwinStrand Biosciences' headquarters is located in Seattle, WA, US.
TwinStrand Biosciences' most recent funding round was for $10.3M (USD) in June 2023.
As of Jun 30, 2023, TwinStrand Biosciences has raised a total of $83.5M (USD).
TwinStrand Biosciences has 71 employees as of Feb 5, 2024.